Paul Hudson told Scrip that while the EU's prioritization on matters such as boosting hydrogen use and electric car batteries was laudable, delivery of healthcare and the innovation associated with it should be "a strategic imperative."
Sanofi CEO Paul Hudson has again spoken out about plans to overhaul EU pharmaceutical legislation and its negative impact on innovative R&D firms, saying further obstacles to market access will hamper the continent's efforts to compete with the US and China.
In response to questions from Scrip at the French giant's annual press conference in Paris this week (1 February), Hudson...
Create an account to read this article
Already a subscriber?
The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.
GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.
PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.
The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
